Ironwood Pharmaceuticals, Inc.
IRWDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Feb 26, 2026 | Jefferies | Amy Li | $3.70(+3%) | $3.60 | StreetInsider |
| Jan 5, 2026 | Craig-Hallum | $5.70(+33%) | $4.27 | TheFly | |
| Jan 4, 2026 | Wells Fargo | $5.00(+17%) | $4.27 | TheFly | |
| Nov 26, 2025 | Craig-Hallum | $3.80(-1%) | $3.83 | TheFly | |
| Apr 14, 2025 | Leerink Partners | Faisal Khurshid | $1.00(+54%) | $0.65 | TheFly |
| Jan 31, 2025 | Wells Fargo | Mohit Bansal | $7.00(+199%) | $2.34 | TheFly |
| Sep 9, 2024 | Leerink Partners | Faisal Khurshid | $5.00(+11%) | $4.51 | TheFly |
| Aug 9, 2024 | Wells Fargo | Mohit Bansal | $12.00(+196%) | $4.05 | TheFly |
| May 22, 2024 | Piper Sandler | David Amsellem | $18.00(+164%) | $6.82 | StreetInsider |
| May 22, 2024 | Wells Fargo | Mohit Bansal | $14.00(+106%) | $6.78 | StreetInsider |
| Apr 22, 2022 | Piper Sandler | David Amsellem | $16.00(+31%) | $12.18 | Pulse 2.0 |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citizens | maintain | Market Outperform | Feb 26, 2026 |
| Wells Fargo | maintain | Equal Weight | Jan 5, 2026 |
| Citizens | upgrade | Market Perform →Market Outperform | Jan 5, 2026 |
| Wells Fargo | maintain | Equal Weight | Nov 11, 2025 |
| Wells Fargo | downgrade | Overweight →Equal Weight | Apr 15, 2025 |
| Jefferies | downgrade | Buy →Hold | Apr 15, 2025 |
| Leerink Partners | maintain | Market Perform | Apr 14, 2025 |
| JMP Securities | maintain | Market Outperform | Jan 30, 2025 |
| Craig-Hallum | maintain | Buy | Jan 22, 2025 |
| Craig-Hallum | maintain | Buy | Aug 9, 2024 |
| Wells Fargo | maintain | Overweight | Aug 9, 2024 |
| Craig-Hallum | maintain | Buy | May 10, 2024 |
| Wells Fargo | maintain | Overweight | Mar 1, 2024 |
| Piper Sandler | maintain | Overweight | Feb 16, 2024 |
| Piper Sandler | maintain | Overweight | May 23, 2023 |
| Piper Sandler | maintain | Overweight | Aug 29, 2022 |
| Wells Fargo | maintain | Equal Weight | Aug 16, 2022 |
| Piper Sandler | maintain | Overweight | Apr 22, 2022 |
| Morgan Stanley | maintain | Equal Weight | Oct 12, 2021 |
| Morgan Stanley | maintain | Equal Weight | Jul 16, 2021 |
| Morgan Stanley | maintain | Equal Weight | Feb 22, 2021 |
| Morgan Stanley | maintain | Equal Weight | Feb 19, 2021 |
| Morgan Stanley | maintain | Equal Weight | Nov 6, 2020 |
| Credit Suisse | maintain | Neutral | Nov 6, 2020 |
| Wells Fargo | downgrade | Overweight →Equal Weight | Sep 30, 2020 |
Earnings History
Next report: Feb 24, 2027 · EPS est. $0.34| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $0.36 | $0.32 | $133.0M | $120.0M |
| Aug 6, 2026 | $0.31 | $0.32 | $113.0M | $114.8M |
| May 7, 2026 | $0.24 | $0.07 | $106.5M | $92.1M |
| Feb 25, 2026 | $-0.01 | $0.02 | $47.7M | $50.9M |
| Nov 10, 2025 | $0.24 | $0.09 | $122.1M | $74.7M |
| Aug 7, 2025 | $0.14 | $-0.02 | $85.2M | $60.8M |
| May 7, 2025 | $-0.23 | $-0.05 | $41.1M | $45.9M |
| Feb 27, 2025 | $0.02 | $0.12 | $90.5M | $93.8M |
News
Ironwood's Q3 earnings beat estimates, lifting shares 6.9%, as stronger Linzess sales expectations and profitability drive a higher 2026 outlook.
Ironwood Pharmaceuticals, Inc. ( IRWD ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Chris Stamm - Vice President of Investor Relations & Communications Thomas McCourt - CEO & Director Tammi Gaskins - Senior Vice President & Chief Commercial Officer Jeffrey Silber - Chief Medical Officer, Head of Research & Drug Development Ronald Silver - Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer Jeff Ruberti - Chief Strategy Officer Conference Call Parti…
Ironwood Pharmaceuticals NASDAQ: IRWD raised its 2026 financial outlook after third-quarter sales of LINZESS reached $325 million, as improved net pricing and prescription demand supported the gastrointestinal drug's performance.
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.24 per share a year ago.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update. “Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cas.
CWA Asset Management Group LLC grew its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) by 71.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 498,643 shares of the biotechnology company's stock after purchasing an additional 208,277 shares during the
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remai.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating on
IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess, due to looming generic competition. IRWD's Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029 and Medicare price cuts impacting margins. Apraglutide's value depends on successful STARS-2 trial results and timely approval, with peak sales modeled conservatively at $456 million.
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood.
Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2 billion and its own revenue forecast to $460–$485 million. Apraglutide, IRWD's pipeline asset for SBS-IF, showed statistically significant Phase 3 results and is key to future value.